%0 Journal Article %1 mueller_meningococcal_2006 %A Mueller, Judith E %A Borrow, Raymond %A Gessner, Bradford D %D 2006 %J Expert Review of Vaccines %K Adolescent, Adult, Africa Carrier Child, Clinical Communicable Disease Diseases, Emerging, Humans, Infant, Meningitis, Meningococcal Meningococcal, Neisseria Outbreaks, Preschool, Sahara, Seroepidemiologic Serogroup Serotyping, South State, Studies, Topic, Trials Vaccination Vaccines, W-135, as meningitidis, of the %N 3 %P 319--36 %R 10.1586/14760584.5.3.319 %T Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines %U http://www.ncbi.nlm.nih.gov/pubmed/16827617 %V 5 %X In the sub-Saharan African meningitis belt there is a region of hyperendemic and epidemic meningitis stretching from Senegal to Ethiopia. The public health approaches to meningitis epidemics, including those related to vaccine use, have assumed that Neisseria meningitidis serogroup A will cause the most disease. During 2001 and 2002, the first large-scale epidemics of serogroup W135 meningitis in sub-Saharan Africa were reported from Burkina Faso. The occurrence of N. meningitidis W135 epidemics has led to a host of new issues, including the need for improved laboratory diagnostics for identifying serogroups during epidemics, an affordable supply of serogroup W135-containing polysaccharide vaccine for epidemic control where needed, and re-evaluating the long-term strategy of developing a monovalent A conjugate vaccine for the region. This review summarizes the existing data on N. meningitidis W135 epidemiology, immunology and vaccines as they relate to meningitis in sub-Saharan Africa.

@article{mueller_meningococcal_2006, abstract = {In the {sub-Saharan} African meningitis belt there is a region of hyperendemic and epidemic meningitis stretching from Senegal to Ethiopia. The public health approaches to meningitis epidemics, including those related to vaccine use, have assumed that Neisseria meningitidis serogroup A will cause the most disease. During 2001 and 2002, the first large-scale epidemics of serogroup W135 meningitis in {sub-Saharan} Africa were reported from Burkina Faso. The occurrence of N. meningitidis W135 epidemics has led to a host of new issues, including the need for improved laboratory diagnostics for identifying serogroups during epidemics, an affordable supply of serogroup W135-containing polysaccharide vaccine for epidemic control where needed, and re-evaluating the long-term strategy of developing a monovalent A conjugate vaccine for the region. This review summarizes the existing data on N. meningitidis W135 epidemiology, immunology and vaccines as they relate to meningitis in {sub-Saharan} Africa.}, added-at = {2011-03-11T10:05:34.000+0100}, author = {Mueller, Judith E and Borrow, Raymond and Gessner, Bradford D}, biburl = {https://www.bibsonomy.org/bibtex/2249c95bd8e05adcac710e047be1a8ea5/jelias}, doi = {10.1586/14760584.5.3.319}, interhash = {778a3477a72886190cc6ff8f71438f65}, intrahash = {249c95bd8e05adcac710e047be1a8ea5}, issn = {1744-8395}, journal = {Expert Review of Vaccines}, keywords = {Adolescent, Adult, Africa Carrier Child, Clinical Communicable Disease Diseases, Emerging, Humans, Infant, Meningitis, Meningococcal Meningococcal, Neisseria Outbreaks, Preschool, Sahara, Seroepidemiologic Serogroup Serotyping, South State, Studies, Topic, Trials Vaccination Vaccines, W-135, as meningitidis, of the}, month = jun, note = {{PMID:} 16827617}, number = 3, pages = {319--36}, shorttitle = {Meningococcal serogroup W135 in the African meningitis belt}, timestamp = {2011-03-11T10:06:39.000+0100}, title = {Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines}, url = {http://www.ncbi.nlm.nih.gov/pubmed/16827617}, volume = 5, year = 2006 }